FDA approves Novartis Egaten for treatment of tablet-sucking disease patients over 6 years of age

tablet stoma, also known as liver sucking infection, is a neglected tropical diseaseThere are about 2.4 million patients worldwide, and another 180 million people are at risktoday, Novartis(http://announced that the U.SFDA(http://approved the company's egaten (triclabendazole) for the treatment of people over the age of 6Egaten is currently the only recommended treatment by the World Health Organization (WHO) for the treatment of tablet-like schistosomiasis, one of thestandards of the WHO's basicdrug(http:// standardWho provides this drug during an outbreak of tablet stoma and is regularly used in endemic countriesFda approval of Egaten will facilitate the importof of the drug to these disease-endemic countries, ensuring adequate drug stocksTablet stoma has been identified by the FDA as a neglected tropical disease, and this approval gives Novartis a priority review voucherNovartis has donated Egaten to the WHO since 2005 and has helped treat 2 million tablet stoma patients in more than 30 countriesin 2018, Novartis renewed its agreement with the WHO and will continue to donate the drug until 2022 It is expected to be delivered to 300,000 patients each year